Clinical Trial Update: Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating HS-10516 combination therapy in patients with advanced renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• HS-10516

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Advanced Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING